CD16-based ROR1-targeted NK cell engager PBA-0405

{
  "id": "MLC-T-ONC-012369",
  "term": "CD16-based ROR1-targeted NK cell engager PBA-0405",
  "field": "Oncology and biomedicine",
  "definition": "An engineered natural killer (NK) cell engager comprised of an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) antibody, with an increased binding affinity to CD16 Fc receptor, with potential immunostimulating and antineoplastic activities. Upon administration, CD16-based ROR1-targeted NK cell engager PBA-0405 targets and binds to ROR1 expressed on tumor cells and simultaneously binds to the activating CD16 Fc receptor expressed on NK cells, thereby bringing ROR1-expressing tumor cells and NK cells together. This stimulates the NK cells, and results in the selective NK cell-mediated tumor cell lysis of ROR1-expressing tumor cells and antibody-dependent cellular cytotoxicity (ADCC). CD16, also known as Fc-gamma receptor III, is normally expressed on the surface of NK cells, neutrophils, monocytes and macrophages, and plays a key role in initiating ADCC. It is often downregulated in certain cancers, thereby inhibiting the anti-tumor immune response. ROR1, also known as neurotrophic tyrosine kinase, receptor-related 1 (NTRKR1), is expressed during embryogenesis and in various hematological and solid malignancies. It plays key roles in tumor cell proliferation and survival.",
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/cd16-based-ror1-targeted-nk-cell-engager-pba-0405/"
}